Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2

doi:10.1056/NEJMc2201933

. 2022 Apr 14;386(15):1475-1477.

doi: 10.1056/NEJMc2201933. Epub 2022 Mar 9.

Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2

Emi Takashita¹, Noriko Kinoshita², Seiya Yamayoshi³, Yuko Sakai-Tagawa³, Seiichiro Fujisaki¹, Mutsumi Ito³, Kiyoko Iwatsuki-Horimoto³, Peter Halfmann⁴, Shinji Watanabe¹, Kenji Maeda², Masaki Imai³, Hiroaki Mitsuya², Norio Ohmagari², Makoto Takeda¹, Hideki Hasegawa¹, Yoshihiro Kawaoka⁵

Affiliations

¹ National Institute of Infectious Diseases, Tokyo, Japan.
² National Center for Global Health and Medicine, Tokyo, Japan.
³ University of Tokyo, Tokyo, Japan.
⁴ University of Wisconsin-Madison, Madison, WI.
⁵ University of Tokyo, Tokyo, Japan yoshihiro.kawaoka@wisc.edu.

PMID: 35263535
PMCID: PMC8929374
DOI: 10.1056/NEJMc2201933

Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2

Emi Takashita et al. N Engl J Med. 2022.

. 2022 Apr 14;386(15):1475-1477.

doi: 10.1056/NEJMc2201933. Epub 2022 Mar 9.

Authors

Affiliations

¹ National Institute of Infectious Diseases, Tokyo, Japan.
² National Center for Global Health and Medicine, Tokyo, Japan.
³ University of Tokyo, Tokyo, Japan.
⁴ University of Wisconsin-Madison, Madison, WI.
⁵ University of Tokyo, Tokyo, Japan yoshihiro.kawaoka@wisc.edu.

PMID: 35263535
PMCID: PMC8929374
DOI: 10.1056/NEJMc2201933

No abstract available

PubMed Disclaimer

Cited by

The Omicron variant of concern: Diversification and convergent evolution in spike protein, and escape from anti-Spike monoclonal antibodies.
Focosi D, McConnell S, Casadevall A. Focosi D, et al. Drug Resist Updat. 2022 Dec;65:100882. doi: 10.1016/j.drup.2022.100882. Epub 2022 Oct 3. Drug Resist Updat. 2022. PMID: 36260961 Free PMC article. Review.
COVID-19 in solid organ transplant recipients after 2 years of pandemic: Outcome and impact of antiviral treatments in a single-center study.
Pinchera B, Buonomo AR, Trucillo E, Susini S, D'Agostino A, Di Filippo I, Tanzillo A, Villari R, Carrano R, Troisi RI, Gentile I. Pinchera B, et al. Front Transplant. 2023 Mar 16;2:1095225. doi: 10.3389/frtra.2023.1095225. eCollection 2023. Front Transplant. 2023. PMID: 38993895 Free PMC article.
An antibody cocktail with broadened mutational resistance and effective protection against SARS-CoV-2.
Sun C, Chi H, Yuan F, Li J, Yang J, Zheng A, Wang F, Sun L, Zhang Y, Hu P, Jiao L, Deng Y, Xie L. Sun C, et al. Sci China Life Sci. 2023 Jan;66(1):165-179. doi: 10.1007/s11427-022-2166-y. Epub 2022 Sep 29. Sci China Life Sci. 2023. PMID: 36184693 Free PMC article.
Safety and Efficacy of Outpatient Treatments for COVID-19: Real-Life Data from a Regionwide Cohort of High-Risk Patients in Tuscany, Italy (the FEDERATE Cohort).
Manciulli T, Spinicci M, Rossetti B, Antonello RM, Lagi F, Barbiero A, Chechi F, Formica G, Francalanci E, Alesi M, Gaggioli S, Modi G, Modica S, Paggi R, Costa C, Morea A, Paglicci L, Rancan I, Amadori F, Tamborrino A, Tilli M, Bandini G, Pignone AM, Valoriani B, Montagnani F, Tumbarello M, Blanc P, Di Pietro M, Galli L, Aquilini D, Vincenti A, Sani S, Nencioni C, Luchi S, Tacconi D, Zammarchi L, Bartoloni A. Manciulli T, et al. Viruses. 2023 Feb 5;15(2):438. doi: 10.3390/v15020438. Viruses. 2023. PMID: 36851654 Free PMC article.
Lopinavir/ritonavir for treatment of non-hospitalized patients with COVID-19: a randomized clinical trial.
Kaizer AM, Shapiro NI, Wild J, Brown SM, Cwik BJ, Hart KW, Jones AE, Pulia MS, Self WH, Smith C, Smith SA, Ng PC, Thompson BT, Rice TW, Lindsell CJ, Ginde AA. Kaizer AM, et al. Int J Infect Dis. 2023 Mar;128:223-229. doi: 10.1016/j.ijid.2022.12.028. Epub 2022 Dec 27. Int J Infect Dis. 2023. PMID: 36581186 Free PMC article. Clinical Trial.

See all "Cited by" articles

References

1. World Health Organization. Weekly epidemiological update on COVID-19. February 1, 2022. (https://www.who.int/publications/m/item/weekly-epidemiological-update-on...).
1. CoVariants. Overview of variants/mutations. February 3, 2022. (https://covariants.org/per-variant).
1. Takashita E, Kinoshita N, Yamayoshi S, et al. Efficacy of antibodies and antiviral drugs against Covid-19 omicron variant. N Engl J Med. DOI: 10.1056/NEJMc2119407. - DOI - PMC - PubMed
1. Uraki R, Kiso M, Imai M, et al. Therapeutic efficacy of antibodies and antivirals against a SARS-CoV-2 Omicron variant. January 19, 2022. (https://assets.researchsquare.com/files/rs-1240227/v1/43f2453c-851d-4f87...). preprint. - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

Supplementary concepts

Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Miscellaneous
- NCI CPTAC Assay Portal

[1] World Health Organization. Weekly epidemiological update on COVID-19. February 1, 2022. (https://www.who.int/publications/m/item/weekly-epidemiological-update-on...).

[2] World Health Organization. Weekly epidemiological update on COVID-19. February 1, 2022. (https://www.who.int/publications/m/item/weekly-epidemiological-update-on...).

[3] CoVariants. Overview of variants/mutations. February 3, 2022. (https://covariants.org/per-variant).

[4] CoVariants. Overview of variants/mutations. February 3, 2022. (https://covariants.org/per-variant).

[5] Takashita E, Kinoshita N, Yamayoshi S, et al. Efficacy of antibodies and antiviral drugs against Covid-19 omicron variant. N Engl J Med. DOI: 10.1056/NEJMc2119407. - DOI - PMC - PubMed

[6] Takashita E, Kinoshita N, Yamayoshi S, et al. Efficacy of antibodies and antiviral drugs against Covid-19 omicron variant. N Engl J Med. DOI: 10.1056/NEJMc2119407. - DOI - PMC - PubMed

[7] Uraki R, Kiso M, Imai M, et al. Therapeutic efficacy of antibodies and antivirals against a SARS-CoV-2 Omicron variant. January 19, 2022. (https://assets.researchsquare.com/files/rs-1240227/v1/43f2453c-851d-4f87...). preprint. - PubMed

[8] Uraki R, Kiso M, Imai M, et al. Therapeutic efficacy of antibodies and antivirals against a SARS-CoV-2 Omicron variant. January 19, 2022. (https://assets.researchsquare.com/files/rs-1240227/v1/43f2453c-851d-4f87...). preprint. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2

Affiliations

Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2

Authors

Affiliations

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Supplementary concepts

Grants and funding

LinkOut - more resources

Full Text Sources

Miscellaneous

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Supplementary concepts

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Miscellaneous